Pell Bio-Med Technology Co., Ltd. (TPE:6949)
Taiwan
· Delayed Price · Currency is TWD 564.00
-27.00 (-4.57%)
At close: Mar 6, 2026
Pell Bio-Med Technology Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | 29.99 | 19.63 | 18.03 | 17.16 | 13.98 |
| Revenue Growth (YoY) | 62.90% | 8.86% | 5.11% | 22.75% | - |
| Cost of Revenue | 39.33 | 31.96 | 44.17 | 28.41 | 18.35 |
| Gross Profit | -9.33 | -12.33 | -26.14 | -11.26 | -4.37 |
| Selling, General & Admin | 142.67 | 135.01 | 145.49 | 82.24 | 54.78 |
| Research & Development | 248.16 | 266.16 | 239.61 | 142.55 | 136.82 |
| Operating Expenses | 390.82 | 401.17 | 385.11 | 224.85 | 191.59 |
| Operating Income | -400.15 | -413.5 | -411.25 | -236.11 | -195.96 |
| Interest Expense | -4.93 | -2.26 | -2.56 | -1.36 | -1.52 |
| Interest & Investment Income | 11.4 | 15.37 | 7.63 | 2.27 | 0.24 |
| Earnings From Equity Investments | -0.03 | 0.11 | 0.11 | -0 | 0.01 |
| Currency Exchange Gain (Loss) | -1.46 | 0.1 | 0.09 | 1.52 | -0.51 |
| Other Non Operating Income (Expenses) | 1.49 | 5.82 | 4.86 | 2.41 | 8.97 |
| EBT Excluding Unusual Items | -393.69 | -394.36 | -401.11 | -231.27 | -188.76 |
| Gain (Loss) on Sale of Investments | 4.61 | -0.62 | - | - | - |
| Gain (Loss) on Sale of Assets | - | -0.14 | -0.13 | - | -0.2 |
| Pretax Income | -389.08 | -395.12 | -401.24 | -231.27 | -188.96 |
| Income Tax Expense | - | - | 0 | - | - |
| Earnings From Continuing Operations | -389.08 | -395.12 | -401.24 | -231.27 | -188.96 |
| Minority Interest in Earnings | 15.37 | 5.7 | 2.48 | 1.14 | - |
| Net Income | -373.72 | -389.42 | -398.76 | -230.13 | -188.96 |
| Net Income to Common | -373.72 | -389.42 | -398.76 | -230.13 | -188.96 |
| Shares Outstanding (Basic) | 59 | 57 | 46 | 39 | 33 |
| Shares Outstanding (Diluted) | 59 | 57 | 46 | 39 | 33 |
| Shares Change (YoY) | 6.22% | 23.33% | 17.94% | 17.87% | - |
| EPS (Basic) | -6.38 | -6.83 | -8.62 | -5.87 | -5.68 |
| EPS (Diluted) | -6.39 | -6.83 | -8.62 | -5.87 | -5.68 |
| Free Cash Flow | -571.76 | -523.91 | -196.48 | -167.48 | -122.32 |
| Free Cash Flow Per Share | -9.76 | -9.18 | -4.25 | -4.27 | -3.68 |
| Gross Margin | -31.12% | -62.79% | -144.96% | -65.61% | -31.27% |
| Operating Margin | -1334.16% | -2106.35% | -2280.52% | -1376.17% | -1402.03% |
| Profit Margin | -1246.01% | -1983.67% | -2211.26% | -1341.32% | -1351.93% |
| Free Cash Flow Margin | -1906.30% | -2668.77% | -1089.53% | -976.14% | -875.12% |
| EBITDA | -381.01 | -394.04 | -392.04 | -217.36 | -178.32 |
| D&A For EBITDA | 19.14 | 19.46 | 19.21 | 18.75 | 17.65 |
| EBIT | -400.15 | -413.5 | -411.25 | -236.11 | -195.96 |
Source: S&P Capital IQ. Standard template. Financial Sources.